Literature DB >> 9236754

Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995.

N Crofts1, C K Aitken.   

Abstract

OBJECTIVE: To assess changes in risk behaviours for transmission of bloodborne viruses and incidences and prevalences of these viruses in a field-recruited cohort of injecting drug users.
DESIGN: Prospective longitudinal cohort study.
SETTING: Metropolitan and rural Victoria, June 1990 to December 1995.
SUBJECTS: 626 current injecting drug users (i.e., who had injected drugs within the previous 12 months). MAIN OUTCOME MEASURES: Seroconversion to HIV and hepatitis B and C viruses (HBV and HCV), risk behaviours for infection.
RESULTS: HIV incidence was very low (0.2 per 100 person-years). HCV incidence was high (10.7 per 100 person-years), but fell throughout the study, although the downward trend did not reach statistical significance. HBV incidence was moderate (1.8 per 100 person-years) and did not fall. Prevalence of risk behaviours, notably sharing needles and syringes, decreased significantly.
CONCLUSIONS: Significant change has occurred in the risk behaviours of the cohort, confirming results of cross-sectional studies of injecting drug use. This change may be responsible for the apparent decline in HIV and HCV incidence. Further studies are needed to monitor the incidence of bloodborne viruses in injecting drug users. Efforts to decrease risk of transmission should continue.

Entities:  

Mesh:

Year:  1997        PMID: 9236754     DOI: 10.5694/j.1326-5377.1997.tb138757.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  29 in total

1.  Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?

Authors:  V D Hope; A Judd; M Hickman; T Lamagni; G Hunter; G V Stimson; S Jones; L Donovan; J V Parry; O N Gill
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  A computer model of the spread of hepatitis C virus among injecting drug users.

Authors:  D Mather; N Crofts
Journal:  Eur J Epidemiol       Date:  1999-01       Impact factor: 8.082

3.  Minimising harm from hepatitis C virus needs better strategies.

Authors:  N Crofts; S Caruana; S Bowden; M Kerger
Journal:  BMJ       Date:  2000-10-07

4.  Changes in injection risk behavior associated with participation in the Seattle needle-exchange program.

Authors:  H Hagan; H Thiede
Journal:  J Urban Health       Date:  2000-09       Impact factor: 3.671

Review 5.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.

Authors:  Enrique R Pouget; Holly Hagan; Don C Des Jarlais
Journal:  Addiction       Date:  2012-04-17       Impact factor: 6.526

6.  Case-reporting of acute hepatitis B and C among injection drug users.

Authors:  Holly Hagan; Nadine Snyder; Eileen Hough; Tianji Yu; Shelly McKeirnan; Janice Boase; Jeffrey Duchin
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

7.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

8.  Changes in blood-borne infection risk among injection drug users.

Authors:  Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

9.  Prevalence and incidence of hepatitis B virus infection in STD clinic attendees in Pune, India.

Authors:  A Risbud; S Mehendale; S Basu; S Kulkarni; A Walimbe; V Arankalle; R Gangakhedkar; A Divekar; R Bollinger; D Gadkari; R Paranjape
Journal:  Sex Transm Infect       Date:  2002-06       Impact factor: 3.519

10.  Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.

Authors:  I van Beek; R Dwyer; G J Dore; K Luo; J M Kaldor
Journal:  BMJ       Date:  1998-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.